Evidence map›Paper›PMID 39567776›Full record

ArticleBJC reports2024

Increased potentiation of 5-fluorouracil induced thymidylate synthase inhibition by 5,10-methylenetetrahydrofolate (arfolitixorin) compared to leucovorin in patients with colorectal liver metastases; The Modelle-001 Trial.

Helena Taflin, Elisabeth Odin, Göran Carlsson, Bengt Gustavsson, Oskar Hemmingsson, Yvonne Wettergren, Krzysztof Urbanowicz, Jacek Turyn, Ryszard T Smolenski, Godefridus J Peters

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJC reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Helena TaflinDepartment of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. helena.taflin@vgregion.se.
Elisabeth OdinDepartment of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Göran CarlssonDepartment of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Bengt GustavssonDepartment of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Oskar HemmingssonDepartment of Diagnostics and Intervention/Surgery, Umeå University, Umeå, Sweden.
Yvonne WettergrenDepartment of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Krzysztof UrbanowiczDepartment of Biochemistry, Medical University of Gdansk, Gdansk, Poland.
Jacek TurynDepartment of Biochemistry, Medical University of Gdansk, Gdansk, Poland.
Ryszard T SmolenskiDepartment of Biochemistry, Medical University of Gdansk, Gdansk, Poland.
Godefridus J PetersDepartment of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers (Amsterdam UMC), Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Funding

IngaBritt and Arne Lundberg Foundation 335/07Isofol Medical AB unconditional grantSwedish Cancer Society CAN 2015/499, CAN 2018, CAN 201025the Swedish state under the LUA/ALF agreement ALFGBG-426941, ALFGBG-586631, ALFGBG-723361, ALFGBG-788901, ALFGBG-966007
6 · The paper itself

Abstract

background5-Fluorouracil (5-FU) is a cornerstone in treatment of colorectal cancer (CRC) and is usually combined with leucovorin (LV) to enhance the antitumour effect by increase thymidylate synthase (TS) inhibition, the key target enzyme for 5-FU. Arfolitixorin (Arfo) is an active form of the reduced folate, [6 R]-5,10-methylenetetrahydrofolate ([6 R]-MeTHF and in contrast to LV, does not need to be metabolized. The Modelle-001 was designed to explore whether a single intravenous bolus injection of Arfo as compared to LV, together with 5-FU increases the inhibition of TS, levels of folate concentrations and polyglutamylation in CRC liver metastases (CRLM) and liver parenchyma. PATIENTS AND

methodsThirty patients with CRLM received either LV (60 mg/m

resultsSignificantly higher MeTHF levels and higher TS inhibition were measured in the Arfo groups compared to LV60, and there was a difference in folate poly-glutamylation between the groups.

conclusionThe Modelle-001 Trial demonstrated significantly higher levels of MeTHF in metastases following Arfo compared to LV. This resulted in a greater increase TS inhibition in metastases although not statistically significant.

Identifiers

PMID39567776
PMCPMC11579015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.